Topical compositions of opioid antagonists and methods for treating skin conditions therewith
Provided are topical compositions comprising opioid antagonists, such as naltrexone or naloxone, or their pharmaceutically acceptable salts, and methods for treating skin conditions, such as those caused by human papillomavirus, therewith.
1. A kit comprising:
a) a unit dose comprising:
naltrexone present in 1% by weight of the unit dose;
cetyl alcohol present in 3.6% by weight of the unit dose;
stearyl alcohol present in 3.6% by weight of the unit dose;
sodium lauryl sulfate present in 0.8% by weight of the unit dose;
nipagin present in 0.1% by weight of the unit dose;
nipasol present in 0.05% by weight of the unit dose;
carboxylpolymethylene present in 0.2% by weight of the unit dose;
propylene glycol present in 5% by weight of the unit dose;
sodium hydroxide present in 0.03% by weight of the unit dose;
white vaseline present in 13.5% by weight of the unit dose;
liquid vaseline present in 5.4% by weight of the unit dose; and
an amount of water sufficient to provide a total of 100% weight for the unit dose; and,
b) a label or printed instructions instructing the topical administration of the unit dose to treat a skin condition caused by a human papillomavirus infection.
2. The kit of claim 1 , further comprising a device that is useful for topically administering the unit dose.
3. The kit of claim 1 , wherein the skin condition is a wart or a lesion.
4. The kit of claim 3 , wherein the wart is a common wart, flat wart, palmar wart, plantar wart, mosaic wart, perinungal wart, or genital wart.
5. The kit of claim 1 , wherein the unit dose is in the form of a cream.
6. A topical composition comprising:
naltrexone present in 1% by weight of the composition;
cetyl alcohol present in 3.6% by weight of the composition;
stearyl alcohol present in 3.6% by weight of the composition;
sodium lauryl sulfate present in 0.8% by weight of the composition;
nipagin present in 0.1% by weight of the composition;
nipasol present in 0.05% by weight of the composition;
carboxylpolymethylene present in 0.2% by weight of the composition;
propylene glycol present in 5% by weight of the composition;
sodium hydroxide present in 0.03% by weight of the composition;
white vaseline present in 13.5% by weight of the composition;
liquid vaseline present in 5.4% by weight of the composition; and
an amount of water sufficient to provide a total of 100% weight for the composition.
7. The topical composition of claim 6 , wherein the topical composition is in the form of a cream.
8. A topical composition consisting essentially of:
naltrexone present in 1% by weight of the composition;
cetyl alcohol present in 3.6% by weight of the composition;
stearyl alcohol present in 3.6% by weight of the composition;
sodium lauryl sulfate present in 0.8% by weight of the composition;
nipagin present in 0.1% by weight of the composition;
nipasol present in 0.05% by weight of the composition;
carboxylpolymethylene present in 0.2% by weight of the composition;
propylene glycol present in 5% by weight of the composition;
sodium hydroxide present in 0.03% by weight of the composition;
white vaseline present in 13.5% by weight of the composition;
liquid vaseline present in 5.4% by weight of the composition; and
an amount of water sufficient to provide a total of 100% weight for the composition.
9. The topical composition of claim 8 , wherein the topical composition is in the form of a cream.
10. A method for treating a skin condition caused by a human papillomavirus infection comprising topically administering to a subject in need thereof an effective amount of the composition of claim 6 .
11. A method for treating a skin condition caused by a human papillomavirus infection, the method comprising topically administering to a subject in need thereof an effective amount of a topical composition comprising:
naltrexone present in 1% by weight of the composition;
cetyl alcohol present in 3.6% by weight of the composition;
stearyl alcohol present in 3.6% by weight of the composition;
sodium lauryl sulfate present in 0.8% by weight of the composition;
nipagin present in 0.1% by weight of the composition;
nipasol present in 0.05% by weight of the composition;
carboxylpolymethylene present in 0.2% by weight of the composition;
propylene glycol present in 5% by weight of the composition;
sodium hydroxide present in 0.03% by weight of the composition;
white vaseline present in 13.5% by weight of the composition;
liquid vaseline present in 5.4% by weight of the composition; and
an amount of water sufficient to provide a total of 100% weight for the composition.
12. The method of claim 11 , wherein the naltrexone has less than about 10% by weight of other stereoisomers.
13. The method of claim 11 , wherein the naltrexone has less than about 5% by weight of other stereoisomers.
14. The method of claim 11 , wherein the skin condition is a wart or a lesion.
15. The method of claim 14 , wherein the wart is a common wart, flat wart, palmar wart, plantar wart, mosaic wart, perinungal wart, or genital wart.
16. The method of claim 11 , wherein the composition is in the form of a cream.
17. The method of claim 11 , wherein the composition is administered to the subject by spreading or spraying the composition onto an affected area of the skin.
18. The method of claim 11 , wherein the composition is administered 1, 2, 3, 4, or 5 times daily.
19. The method of claim 11 , wherein the composition is administered in an effective amount to deliver a total daily dose of naltrexone up to about 150 mg/cm 2 of skin.
20. The method of claim 1 , wherein the composition is administered in an effective amount to deliver a total daily dose of naltrexone about 10 mg/cm 2 to about 100 cm 2 of skin.
21. The method of claim 11 , wherein the composition is administered in an effective amount to deliver a total daily dose of naltrexone about 50 mg/cm 2 of skin.
22. The method of claim 11 , further comprising administering to the subject one or more additional agents effective to treat the skin condition.